$25.75
0.63%
Nasdaq, Oct 03, 10:09 pm CET
ISIN
US07373V1052
Symbol
BEAM

Beam Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Beam Therapeutics Inc Classifications & Recommendation:

Buy
86%
Hold
14%

Beam Therapeutics Inc Price Target

Target Price $42.84
Price $25.75
Potential
Number of Estimates 16
16 Analysts have issued a price target Beam Therapeutics Inc 2026 . The average Beam Therapeutics Inc target price is $42.84. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 21 analysts: 18 Analysts recommend Beam Therapeutics Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Beam Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Beam Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 63.52 44.50
83.18% 29.94%
EBITDA Margin -619.71% -1,045.38%
1,395.95% 68.69%
Net Margin -593.10% -1,001.30%
1,590.35% 68.82%

17 Analysts have issued a sales forecast Beam Therapeutics Inc 2025 . The average Beam Therapeutics Inc sales estimate is

$44.5m
Unlock
. This is
26.16% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$69.2m 14.81%
Unlock
, the lowest is
$15.7m 73.98%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $63.5m 83.18%
2025
$44.5m 29.94%
Unlock
2026
$52.6m 18.20%
Unlock
2027
$59.5m 13.05%
Unlock
2028
$128m 116.07%
Unlock
2029
$456m 254.69%
Unlock
2030
$887m 94.58%
Unlock
2031
$876m 1.18%
Unlock
2032
$1.2b 35.93%
Unlock

8 Analysts have issued an Beam Therapeutics Inc EBITDA forecast 2025. The average Beam Therapeutics Inc EBITDA estimate is

$-465m
Unlock
. This is
9.72% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-423m 0.35%
Unlock
, the lowest is
$-486m 14.64%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-394m 151.58%
2025
$-465m 18.18%
Unlock
2026
$-486m 4.53%
Unlock
2027
$-528m 8.58%
Unlock
2028
$-250m 52.69%
Unlock
2029
$-208m 16.90%
Unlock
2030
$-138m 33.66%
Unlock

EBITDA Margin

2024 -619.71% 1,395.95%
2025
-1,045.38% 68.69%
Unlock
2026
-924.52% 11.56%
Unlock
2027
-888.02% 3.95%
Unlock
2028
-194.43% 78.11%
Unlock
2029
-45.55% 76.57%
Unlock
2030
-15.53% 65.91%
Unlock

18 Beam Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Beam Therapeutics Inc net profit estimate is

$-446m
Unlock
. This is
11.79% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-400m 0.34%
Unlock
, the lowest is
$-486m 21.84%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-377m 184.27%
2025
$-446m 18.28%
Unlock
2026
$-455m 2.06%
Unlock
2027
$-480m 5.59%
Unlock
2028
$-380m 20.88%
Unlock
2029
$-272m 28.53%
Unlock
2030
$-168m 38.23%
Unlock
2031
$-8.2m 95.10%
Unlock
2032
$134m 1,733.82%
Unlock

Net Margin

2024 -593.10% 1,590.35%
2025
-1,001.30% 68.82%
Unlock
2026
-864.62% 13.65%
Unlock
2027
-807.57% 6.60%
Unlock
2028
-295.71% 63.38%
Unlock
2029
-59.59% 79.85%
Unlock
2030
-18.92% 68.25%
Unlock
2031
-0.94% 95.03%
Unlock
2032
11.28% 1,300.00%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.58 -4.42
166.28% 3.49%
P/E negative
EV/Sales 32.69

18 Analysts have issued a Beam Therapeutics Inc forecast for earnings per share. The average Beam Therapeutics Inc EPS is

$-4.42
Unlock
. This is
13.33% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.97 1.79%
Unlock
, the lowest is
$-4.82 23.59%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.58 166.28%
2025
$-4.42 3.49%
Unlock
2026
$-4.51 2.04%
Unlock
2027
$-4.77 5.76%
Unlock
2028
$-3.77 20.96%
Unlock
2029
$-2.69 28.65%
Unlock
2030
$-1.66 38.29%
Unlock
2031
$-0.08 95.18%
Unlock
2032
$1.33 1,762.50%
Unlock

P/E ratio

Current -6.60 54.40%
2025
-5.82 11.85%
Unlock
2026
-5.71 1.89%
Unlock
2027
-5.40 5.43%
Unlock
2028
-6.83 26.48%
Unlock
2029
-9.56 39.97%
Unlock
2030
-15.47 61.82%
Unlock
2031
-315.56 1,939.82%
Unlock
2032
19.32 106.12%
Unlock

Based on analysts' sales estimates for 2025, the Beam Therapeutics Inc stock is valued at an EV/Sales of

32.69
Unlock
and an P/S ratio of
58.54
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 24.13 704.33%
2025
32.69 35.46%
Unlock
2026
27.65 15.39%
Unlock
2027
24.46 11.54%
Unlock
2028
11.32 53.72%
Unlock
2029
3.19 71.81%
Unlock
2030
1.64 48.61%
Unlock
2031
1.66 1.19%
Unlock
2032
1.22 26.43%
Unlock

P/S ratio

Current 43.22 638.09%
2025
58.54 35.43%
Unlock
2026
49.53 15.39%
Unlock
2027
43.81 11.54%
Unlock
2028
20.27 53.72%
Unlock
2029
5.72 71.81%
Unlock
2030
2.94 48.61%
Unlock
2031
2.97 1.20%
Unlock
2032
2.19 26.43%
Unlock

Current Beam Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Sep 15 2025
Barclays
Locked
Locked
Locked Aug 06 2025
Barclays
Locked
Locked
Locked May 07 2025
Guggenheim
Locked
Locked
Locked May 07 2025
Wells Fargo
Locked
Locked
Locked May 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 07 2025
B of A Securities
Locked
Locked
Locked Mar 28 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 15 2025
Locked
Barclays:
Locked
Locked
Aug 06 2025
Locked
Barclays:
Locked
Locked
May 07 2025
Locked
Guggenheim:
Locked
Locked
May 07 2025
Locked
Wells Fargo:
Locked
Locked
May 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 07 2025
Locked
B of A Securities:
Locked
Locked
Mar 28 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today